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Despite extensive scientific progress in the melanoma field, treatment of advanced stage
melanoma with chemotherapeutics and biotherapeutics has rarely provided response
rates higher than 20%. In the past decade, targeted inhibitors have been developed for
metastatic melanoma, leading to the advent of more personalized therapies of geneti-
cally characterized tumors. Here we review current melanoma treatments and emerging
targeted molecular therapies. In particular we discuss the mutant BRAF inhibitors Vemu-
rafenib and Dabrafenib, which markedly inhibit tumor growth and advance patients’ overall
survival. However this response is almost inevitably followed by complete tumor relapse
due to drug resistance hampering the encouraging initial responses. Several mechanisms
of resistance within and outside the MAPK pathway have now been uncovered and have
paved the way for clinical trials of combination therapies to try and overcome tumor relapse.
It is apparent that personalized treatment management will be required in this new era of
targeted treatment. Circulating tumor cells (CTCs) provide an easily accessible means of
monitoring patient relapse and several new approaches are available for the molecular char-
acterization of CTCs. Thus CTCs provide a monitoring tool to evaluate treatment efficacy
and early detection of drug resistance in real time.We detail here how advances in the mol-
ecular analysis of CTCs may provide insight into new avenues of approaching therapeutic
options that would benefit personalized melanoma management.
Keywords: metastatic melanoma, personalized treatment, targeted therapy, drug resistance, circulating tumor cells
INTRODUCTION
Melanoma is an aggressive cutaneous cancer that arises from
melanocyte cells within the basal layer of the epidermis. This
aggressive malignancy accounts for more than 80% of skin can-
cer deaths and its incidence is increasing worldwide (Linos et al.,
2009). Cutaneous melanoma arises from the transformation of
melanocytes by the accumulation of mutations in genes that reg-
ulate cell differentiation and proliferation. The disease manifests
itself as clinically and genetically distinct subgroups indicating the
need for patient-specific treatment strategies.
In the past decade, since the discovery of key mutations and
activated pathways that drive the development of melanoma
(Davies et al., 2002), new targeted therapies have been devel-
oped, with mixed success. In the fore front of these is a molecule
that specifically inhibits the mutated BRAFV600E kinase, Vemu-
rafenib, which was approved by the FDA in 2011 as a thera-
peutic option for treatment of unresectable metastatic melanoma
(Chapman et al., 2011). Given the success of this treatment and
other treatment advances detailed below, new guidelines for the
treatment of melanoma are evolving (Fox et al., 2013). More-
over, deep sequencing analyses have revealed new potential tar-
gets and much has been learned about the molecular basis of
melanoma genesis. A clearer landscape of the mutation profile
of melanoma is emerging and with it new potential therapeutic
targets.
MUTATIONS IN MELANOMA
The most commonly observed recurrent mutations in melanoma
reside within the MAPK pathway. The MAPK/Extracellular signal-
regulated kinase (ERK) signaling pathway is commonly activated
in melanoma by mutations in BRAF (in 50% of melanomas),
NRAS (10–20%), and less frequently in MEK1 and MEK2 (∼8%)
(Davies et al., 2002; Curtin et al., 2005; Murugan et al., 2009;
Dutton-Regester and Hayward, 2012). Around 70–95% of all
BRAF mutations are a V600E substitution, with an alternative
V600K in 5–30% of the cases. BRAF and NRAS mutations are
usually exclusive with a Q61R substitution in ∼60% of NRAS
mutated cases (Colombino et al., 2012).
Mutations in upstream tyrosine kinase receptors such as KIT
(10%, mainly in acral and mucosal melanoma), ERBB4 (∼19%)
(Prickett et al., 2009), and FGFR2 (∼10%) (Gartside et al., 2009),
can activate both the MAPK/ERK and the PI3K/AKT pathways.
Activating mutations in the kinases PI3K (∼3%) and AKT
(∼1%) have also been reported, albeit at lower frequencies (Davies
et al., 2002; Omholt et al., 2006). More common are mutations or
deletions in the tumor suppressor gene PTEN (∼10–27%),respon-
sible for the negative regulation of the PI3K/AKT pathway (Paraiso
et al., 2011). Mutations in PREX2 (14%), a negative regulator of
PTEN, have been described recently (Berger et al., 2012).
Another tumor suppressor gene commonly altered in
melanoma is CDKN2A (∼50%) which regulates the pRB and p53
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pathways (Flores et al., 1996). Additional driver mutations in TP53
(∼20%), CDK4 (∼3%), and RB1 (∼3%) have also been described,
as well as a hot-spot in the adapter protein TRRAP (4%) (Wei
et al., 2011). Furthermore, many mutations have been reported in
other components that control cellular proliferation, angiogenesis
and apoptosis, including glutamate receptors GRIN2A (33%) (Wei
et al., 2011) and GRM3 (16%) (Prickett et al., 2011), G-protein
GQNA (50% malignant blue nevi and 46% of uveal melanomas)
(Van Raamsdonk et al., 2010), and the kinases MAP3K5 (9%) and
MAP3K9 (15%) (Stark et al., 2012). Other genomic aberrations
include amplifications in MITF (4%), CDK4 (3%), CCND1 (11%)
and TERT (13%), and deletions in CDKN2A (38%) (Hodis et al.,
2012).
A recent study described five new genes containing potential
driver mutations, PPP6C, RAC1, SNX31, TACC1, STK19, and
ARID2. The serine/threonine phosphatase PPP6C which nega-
tively regulates the CCND1 oncogene, appears mutated in 12%
of sun-exposed melanomas (Krauthammer et al., 2012), with the
R264C substitution in 3% of cases (Hodis et al., 2012). RAC1, a
RAS-related member of the Rho family of GTPases which regulate
cytoskeleton rearrangements, contains the P29S substitution in
around 4% of melanomas (Hodis et al., 2012). SKT19, a predicted
kinase of known function, contains a D89N mutation in around
5% of melanomas.
Taken together, these recent tour de force studies reveal the
complex array of mutations and genetic aberrations associated
with melanoma genesis. Nevertheless it seems apparent that no
other single mutation will have the same level of frequency as
BRAFV600E, which is mutated in approximately 50% of human
melanomas (Davies et al., 2002). Further analyses to discern dri-
ver from passenger mutations as well as their mechanisms of action
are required to clarify the intervention targets and rational com-
bination strategies likely to provide the most successful outcomes.
What is abundantly clear, however, is that future therapies will
require previous knowledge of the patient’s mutational status to
guide the most appropriate intervention in a personalized fashion.
So far only the targeted inhibitor of BRAFV600E Vemurafenib has
been approved for treatment of melanoma, however we foresee in
the near future that an arsenal of therapies will be available based
on the tumor genotype. Thus, it is envisaged that tumor specimens
will in future, be subjected to targeted sequencing of all the poten-
tial mutation hot-spots for which there are therapeutic targets or
which affect treatment outcome. However given the inter- and
intra-tumor heterogeneity analysis of circulating melanoma cells
may provide a comprehensive and sensitive tool for determining
the overall mutation status of a patient’s tumors.
CLINICAL ADVANCES IN MELANOMA TARGETED THERAPIES
BRAFV600E INHIBITORS
Developments in molecular targeted therapies (Figure 1; Table 1)
have predominantly focused on targeting the BRAF, MEK,
or c-KIT kinases located within the MAPK pathway. Two
FIGURE 1 | MAPK and PI3K/AKT pathways, therapeutic targets for
melanoma and resistance to Vemurafenib. Vemurafenib and Dabrafenib
are specific for BRAFV600E, while Sorafenib and RAF-265 are pan-RAF
inhibitors. Imatinib, Nilotinib, Dasatinib, and Sunitinib target and inhibit
c-KIT. Selumetinib and Trametinib inhibit MEK activity. Temsirolimus and
Everolimus inhibit the mTOR protein. Resistance to Vemurafenib arises
from MAPK pathway reactivation by (1) a MEK1C121S mutation, (2)
NRASQ61R/K mutations, (3) COT1 overexpression, (4) alternatively spliced
variants of BRAFV600E or amplification of the mutant BRAF allele, (5)
Overexpression or activation of RTKs (PDGFRβ or IGF1R) bypasses mutant
BRAF and activates ERK via CRAF-MEK or through independent ERK
mechanisms by activating the PI3K/AKT pathway.
Frontiers in Oncology | Cancer Genetics March 2013 | Volume 3 | Article 54 | 2
Klinac et al. Personalized treatment of metastatic melanoma
Table 1 | Anti-cancer inhibitors undergoing testing for treatment of cutaneous melanoma.
Pathway Treatment type Target protein Specific mutation Trial Effectiveness
MAPK Vemurafenib
(PLX4032)
BRAF V600E/K Phase I/II (Chapman et al., 2011) CR–PR=1.8–98%
NCT01006980 (completed) RR=48%
PFS=5.3 months
OSR=84% at 6 months
Phase III – (updated BRIM-3)
(Chapman et al., 2012)
RR=48.4%
Hazard ratio PFS=0.26 (95% CI
0.2–0.33)
OSR=55% at 13.2 monthsNCT01006980 (ongoing study)
Phase II (Sosman et al., 2012) CR–PR=6–47%
NCT00949702 (completed) OR=53%
PFS=6.8 months
OS=15.9 months
Phase II N/A
NCT01586195 (recruiting participants)
Phase II N/A
NCT01474551 (recruiting participants)
Dabrafenib
(GSK2118436)
BRAF V600E/K Phase I (Falchook et al., 2012b) CR–PR=50–70%
NCT00880321 (completed) RR=69%
PFS=5.6 months
OSR=47%>6 months
Phase II (Long et al., 2012) PFS=4 months
NCT01266967 (ongoing study) OS>7.8 months
Phase II N/A
NCT01153763 (ongoing study)
Phase III (Hauschild et al., 2012) CR–PR=3–47%
NCT01227889 (ongoing study) OR=50%
PFS=5.1 months
Hazard ratio OS=0.61 (95% CI
0.25–1.48)
Sorafenib
(BAY43-9006,
Nexavar)
ARAF, BRAF,
CRAF, VEGF2/3,
KIT PDGFR
Not specified Phase I (Pecuchet et al., 2012) OR=21% at 10 months
(Completed) PFS=3.6 months
OSR=33% at 11 months
Phase I N/A
NCT01303341 (recruiting participants)
Phase I N/A
NCT00565968 (recruiting participants)
Phase I N/A
NCT01078961 (recruiting participants)
RAF-265
(CHIR-265)
ARAF, BRAF,
CRAF, VEGFR
Not specified Phase I/II N/A
NCT00304525 (ongoing study)
Phase Ib N/A
NCT01352273 (ongoing study)
Selumetinib
(AZD6244,
PD0325901)
MEK BRAF V600E Phase II N/A
NCT00888134 (ongoing study)
Phase II N/A
NCT00936221 (ongoing study)
Phase II N/A
NCT01519427 (recruiting participants)
(Continued)
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Table 1 | Continued
Pathway Treatment type Target protein Specific mutation Trial Effectiveness
Trametinib
(GSK1120212,
JTP-74057)
MEK BRAF V600E/K Phase II (Kim et al., 2011) CR–PR=4–30%
NCT01037127 (ongoing study) SD=47%
RR=33%
Phase III (METRIC) (Robert et al., 2012) OR=24%
NCT01245062 (ongoing study) PFS=4.8 months
Hazard ratio OS=0.53 (95% CI
0.3–0.94)
Phase I/II trial N/A
NCT01584648 (recruiting participants)
Phase II N/A
NCT01619774 (recruiting participants)
Phase III N/A
NCT01597908 (recruiting participants)
PI3K/AKT Sunitinib
(CGP57148,
Gleevec, Glivec)
c-KIT Not specified Phase I/II N/A
NCT00859326 (recruiting status
unknown)
Imatinib
(ST1571)
c-KIT Not specified Phase II N/A
NCT00424515 (ongoing study)
Phase II N/A
NCT00470470 (recruiting participants)
Nilotinib
(AMN107)
c-KIT Not specified Phase II N/A
NCT01168050 (recruiting participants)
Phase II N/A
NCT01099514 (recruiting participants)
Dasatinib
(BMS-354825,
Bosulif, Sprycel)
c-KIT KIT exon 11 and 13 Phase II
NCT01092728 (recruiting participants)
N/A
Temsirolimus
(CCI-779)
mTOR Not specified Phase II (Margolin et al., 2005) N/A
California cancer consortium
(completed)
Phase II (Dronca et al., 2010) PR=8%
NCT00521001 (completed) PFS=2.4 months
OS=8.6 months
Everolimus
(RAD001)
mTOR Not specified Phase II N/A
NCT00976573 (recruiting participants)
Immuno-
suppression
blockage
Ipilimumab
(MDX-010,
BMS-734016)
CTLA-4 Not specified Phase I (Hodi et al., 2010) CR–PR=0–13%
NCT00094653 (completed) OR=10.9%
PFS∼30% at 12 weeks
OS=23.5% 2 years
Phase III (Robert et al., 2011) CR–PR=1.6–13.6%
NCT00324155 (ongoing study) OR=15.2%
PFS∼35% at 12 weeks
OS=28.5% 2 years
Phase II (Di Giacomo et al., 2012) CR–PR=10–30%
NCT01654692 (ongoing study) RR=40%
PFS>5 months
OS=50%>1 year
Phase I/II N/A
NCT01400451 (recruiting participants)
(Continued)
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Table 1 | Continued
Pathway Treatment type Target protein Specific mutation Trial Effectiveness
MDX-1106
(BMS-93558 or
ONO-4538)
PD-1 Not specified Phase Ib (Topalian et al., 2012) CRR=28% for 1 year
NCT00730639 (ongoing study) PFS at 24 weeks=41%
Phase I N/A
NCT01621490 (recruiting participants)
Phase I N/A
NCT01176474 (recruiting participants)
Phase III N/A
NCT01721772 (recruiting participants)
MK-3475 PD-1 Not specified Phase I (Hamid, 2012) RR=51%
NCT01295827 (recruiting participants) CR=9%
BMS-936559 PD-L1 Not specified Phase I (Brahmer et al., 2012) OR=17%
NCT00729664 (recruiting participants) PFS at 24 weeks=42%
PR, partial response; RR, response rate; CR, complete response; OR, overall response; PFS, progression-free survival; OS, overall survival; OSR, overall survival rate;
SD, stable disease; N/A, data not available.
selective BRAFV600E inhibitors Vemurafenib (commonly known
as PLX4032, RG7204, or Zelboraf) and GSK2118436 (Dabrafenib)
have demonstrated significant anti-tumor activity (Anforth et al.,
2012; Falchook et al., 2012b; Long et al., 2012).
Vemurafenib inhibits the mutant BRAFV600E protein and also
has inhibitory actions against other kinases, including CRAF,
ARAF, and wild-type BRAF (Bollag et al., 2010). The phase III clin-
ical trial (NCT01006980) compared the effect of oral Vemurafenib
treatment (960 mg twice daily) to Dacarbazine (1000 mg/m2 intra-
venous every 3 weeks) in a total of 675 metastatic melanoma
patients with the BRAFV600E mutation. Response rates of more
than 48% were observed in Vemurafenib treated patients com-
pared to a 5% response rate in the Dacarbazine arm. The esti-
mated median PFS (progression-free survival) for Vemurafenib
was 5.3 months with an 84% overall survival at 6 months, com-
pared to a median PFS of 1.6 months with a 64% overall survival
at 6 months for Dacarbazine (Chapman et al., 2011). As a result of
this study, Vemurafenib was approved by the US FDA in August
2011 as a new treatment standard for patients with unresectable or
metastatic melanoma with a BRAFV600E mutation (US Food and
Drug Administration, 2011).
A separate phase II clinical trial of Vemurafenib treatment for
patients with an activating BRAFV600 mutation (NCT00949702)
included 132 previously treated melanoma patients. Patients were
assessed for response rate, duration of the response, and over-
all survival after Vemurafenib treatment (Sosman et al., 2012).
Patients received oral Vemurafenib at a dose of 960 mg twice daily.
A complete response was reported in 6% (n= 8) of patients and
a partial response was achieved in 47% (n= 62) of individuals
with an overall response rate of 53%. Stable disease was noted in
29% (n= 38) of patients, while 14% (n= 18) of subjects demon-
strated progressive disease. At the time of data analysis, patients
demonstrated a median PFS of 6.8 months and an overall survival
of 15.9 months (Sosman et al., 2012).
Common adverse events related to Vemurafenib treatment
included fatigue, skin rash, joint pain, photosensitivity, nausea,
and development of cutaneous squamous cell carcinomas (SCC)
or keratoacanthoma (KA). From the 130 patients that presented
adverse reactions to Vemurafenib, 34 patients developed a Grade
III SSC or KA. More recently, Su et al. (2012a) reported the para-
doxical activation of the MAPK pathway by Vemurafenib; Vemu-
rafenib accelerates the growth of pre-existing cancerous lesions
(SSC and KA) via upstream MAPK signaling, such as through
HRASQ61L (Su et al., 2012a).
At the 2012 ASCO Annual Meeting, results were reported of
the ongoing phase III (BRIM-3) randomized trial (NCT01006980)
comparing Vemurafenib with Dacarbazine in previously untreated
patients with BRAFV600E melanomas (Chapman et al., 2012). In
this trial, a total of 675 patients were randomly assigned to receive
either 960 mg of oral Vemurafenib twice daily or Dacarbazine
1000 mg/m2 intravenously every 3 weeks. The median overall sur-
vival with Vemurafenib was 13.2 months compared to 9.6 months
with Dacarbazine. The 12-month overall survival rates were 55%
forVemurafenib and 43% for the Dacarbazine patients. The hazard
ratio for death was 0.62 in favor of the Vemurafenib patients. This
study confirms the finding that a targeted therapy, Vemurafenib,
improves overall survival rates for patients relative to treatment
with a chemotherapeutic agent, Dacarbazine (Chapman et al.,
2012).
Dabrafenib (GSK2118436) is a reversible, potent ATP-
competitive inhibitor that blocks BRAFV600E kinase fivefold more
effectively that it does CRAF or wild-type BRAF. A phase I
dose-escalation trial (NCT00880321) reported active inhibition
of melanoma and brain metastases in response to Dabrafenib
treatment (Falchook et al., 2012b). A total of 156 patients with
metastatic melanoma were involved in the study; 3 of these patients
were BRAF wild-type with the other 153 presenting with vari-
ous BRAFV600 mutations. Overall, 47% of metastatic melanoma
patients with a BRAFV600E mutation maintained successful treat-
ment for more than 6 months. A partial or complete response
to Dabrafenib (dosage of 150 mg twice daily) was also noted in
18 BRAFV600K mutation positive melanoma patients who were
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given varied doses of Dabrafenib (100–150 mg either once daily or
twice daily). Of these,39% (n= 7) demonstrated a partial response
to treatment and 22% (n= 4) had a complete response to treat-
ment. The median PFS for eight patients receiving Dabrafenib
150 mg twice daily was 5.6 months. For three patients with wild-
type BRAF, PFS was 1.5 months. The PFS for patients present-
ing complex BRAF mutations (K601 and V600-K601insdelE) was
1.8 months. For BRAFV600E patients who did not respond to treat-
ment, PFS was 4.2 month. This study found Dabrafenib to be an
effective inhibitor of mutant BRAFV600E/K in metastatic melanoma
patients with brain metastases and other solid tumors (Falchook
et al., 2012b).
A follow-up phase II multicenter trial (NCT01266967) was con-
ducted over six countries, with a total enrollment of 172 metastatic
melanoma patients with confirmed BRAFV600E (n= 139, 81%)
or BRAFV600K (n= 33, 19%) mutations and a brain metasta-
sis. Patients were divided into two cohorts: cohort A consisted
of patients who had not received previous treatment for brain
metastases and cohort B, subjects had progressive brain metas-
tases after previous treatment. All patients received 150 mg of
oral Dabrafenib twice daily. In both BRAFV600E and BRAFV600K
patients, overall survival was greater than 7.8 months. Interest-
ingly, the overall response was lower amongst patients with a
BRAFV600K melanoma than it was in BRAFV600E patients. For
example, in cohort A intracranial responses were achieved in
39.2% (n= 29) of BRAFV600E patients compared to the 6.7%
(n= 1) response obtained in BRAFV600K melanomas (Long et al.,
2012).
An ongoing phase III randomized controlled trial
(NCT01227889) reported recently showed an overall improved
PFS for patients with BRAFV600E mutant metastatic melanoma
treated with Dabrafenib compared with Dacarbazine (Hauschild
et al., 2012). A total of 187 patients received Dabrafenib (150 mg
twice daily) and 63 patients were given intravenous Dacarbazine
(1000 mg/m2 every 3 weeks). The median PFS for the Dabrafenib
patients was 5.1 months compared to 2.7 months for the Dacar-
bazine patients. The complete response rate for the Dabrafenib
patients was 3% (n= 6) compared with a 2% (n= 1) response rate
for the Dacarbazine group. A 47% (n= 87) partial response rate
was reported for the Dabrafenib subjects with a 5% (n= 3) partial
response rate observed in the Dacarbazine group. As this clinical
study is ongoing, the current overall survival hazard ratio reported
is 0.61 (95% CI 0.25–1.48) in favor of Dabrafenib (Hauschild et al.,
2012) but in contrast to the Vemurafenib phase III trial, in this trial
all patients randomized to Dacarbazine were given the opportunity
to cross over to Dabrafenib on progression masking any over-
all survival difference. Interestingly, Dabrafenib treatment showed
less phototoxic reactions and proliferative epidermal lesions (SCC
and KA) in only 6% of patients, compared to 11% under Vemu-
rafenib treatment. On the other hand, inflammatory syndromes
with fever, rare with Vemurafenib (6%), were recorded in 20% of
Dabrafenib treated patients (Hauschild et al., 2012; Sosman et al.,
2012).
Overall, treatment with Vemurafenib or Dabrafenib confers a
survival advantage in metastatic melanoma patients and presents
an encouraging treatment option. However, response to these two
inhibitors is restricted to only a proportion of melanoma patients.
Efforts to treat metastatic melanoma patients with broad spectrum
multi-kinase inhibitors, as detailed below, would seem to be more
broadly efficacious since they are independent of BRAF activating
mutations, but in fact they are less so.
MULTI-KINASE INHIBITORS
RAF multi-kinase inhibitor, Sorafenib (BAY 43-9006 or Nexavar),
is an oral agent that inhibits many cellular targets including:
VEGFR-2, platelet-derived growth factor receptor (PDGFR), c-
KIT, FLT-3, CRAF, and BRAF. In vitro studies have demonstrated
that Sorafenib induces cell cycle arrest and apoptosis in melanoma
cell lines via MAPK activity inhibition (Gray-Schopfer et al.,
2007). Sorafenib has been granted FDA approval for the treat-
ment of advanced clear-cell renal carcinoma (Wilhelm et al., 2006),
based on a randomized trial demonstrating prolonged PFS in
patients (Escudier et al., 2007). However, it has demonstrated
modest treatment outcomes in patients with advanced melanoma
(Eisen et al., 2006; Flaherty, 2006). A recent phase II clinical trial
(NCT00119249) confirmed that Sorafenib monotherapy had lim-
ited activity in patients with metastatic melanoma regardless of
the BRAFV600E mutational status of their tumor tissue (Ott et al.,
2010). By contrast, a more recent study of 28 melanoma patients,
showed that after 10 months follow-up there was a 21% overall
response rate with a median PFS of 3.6 months and a 1-year sur-
vival rate of 33% (Pecuchet et al., 2012). Although Sorafenib has
not shown increased PFS in melanoma patients there are ongoing
clinical trials (NCT01303341, NCT00565968, and NCT01078961)
currently recruiting participants which are investigating the effects
of Sorafenib in combination with other treatments.
Broad spectrum kinase inhibitors RAF-265 and XL281, known
to target ARAF, BRAF, CRAF genes, and VEGFR receptors, have
greater effectiveness and modestly improved selectivity for tar-
geting BRAF compared with Sorafenib, in preclinical models
and in patients with advanced solid tumors (Venetsanakos et al.,
2006; Schwartz et al., 2009). A study using orthotropic implants
of metastatic melanoma in mice, showed a 41% response rate,
with more than 50% reduction in tumor growth after treat-
ment with RAF-265 (Su et al., 2012b). Since the development
of more potent BRAF inhibitors, clinical evaluation of RAF-265
inhibitor as a single-agent treatment for melanoma patients is not
a strong focus. There is however, an ongoing phase I/II clinical trial
(NCT00304525) evaluating the maximum tolerated dose of RAF-
265 as an oral agent in patients with locally advanced or metastatic
melanoma. Another ongoing phase Ib study (NCT01352273) is
investigating the combination of the MEK inhibitor (MEK162)
with RAF-265 in patients with advanced solid tumors harboring
BRAFV600E mutations and/or RAS mutations.
It is critical for the field of melanoma therapeutics, to enhance
the longevity of the successful responses obtained with BRAF
inhibitors. Therefore the focus now is on novel inhibitors designed
to target other kinases within the MAPK pathway, for use indi-
vidually or in combination strategies as additional treatment
options.
NRAS INHIBITION
Inhibition of NRAS has proven challenging as its GTPase activity
has not allowed for successful design of specific small-molecule
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antagonists. RNA (siRNA)-mediated depletion of NRAS in two
melanoma cell lines (224 and BL, which harbor a Q61R NRAS
mutation) inhibits proliferation and renders cells more sensitive to
chemotherapy (Eskandarpour et al., 2005). A single-agent, single-
arm phase II trial conducted with metastatic melanoma patients
investigated Farnesyltransferase inhibitors (FTI’s) which block far-
nesylation, the key activating post-translational modification of
RAS (Sebti, 2005). The outcome of this trial using the FTI Tipi-
farnib (otherwise known as R115777), showed a low response in
the first 14 patients which led to early closure of the trial (Gajewski
et al., 2006). However, in this trial patients were not selected based
on the presence or absence of NRAS mutations.
Due to the absence of successful specific RAS inhibitors for the
treatment of melanoma, there are currently no registered clinical
trials for the evaluation of NRAS inhibitors. Inhibition of RAS
effector pathways would appear to be a more favorable option and
investigations of these are underway. The next kinase in the path-
way, MEK, has proven to be a more favorable target (Flaherty et al.,
2012a).
MEK INHIBITORS
Selumetinib (also known as AZD6244, ARRY-142886, or
PD0325901) is a selective non-ATP-competitive inhibitor of
the mitogen-activated protein/ERK kinase (MEK1/2) (Figure 1)
(Davies et al., 2007). A successful early phase I trial with Selume-
tinib, opened the door for MEK inhibitors to be considered as
efficacious for patients with metastatic cancer (Lorusso et al.,
2005). In this phase I study, the BRAF status of most patients
was unknown. However, two cases with known BRAFV600E and
one with an NRAS (not specified) mutation, displayed a pos-
itive response to treatment (Lorusso et al., 2005; Davies et al.,
2007). A later phase II single-agent trial compared Selumetinib to
Temozolomide. In this study of 100 genetically tested patients, 67
were BRAF and 24 were NRAS positive patients. Only six patients
(five of them BRAF positive) receiving Selumetinib showed an
11% response rate. It is unclear why this trial showed such low
response rates in patients and did not show a significant PFS rate
relative to Temozolomide (Dummer et al., 2008). However a cur-
rently recruiting, phase II clinical trial (NCT01519427) will be
investigating the efficacy of a combination of Selumetinib and
the AKT inhibitor MK2206, for BRAF positive stage III and/or
IV melanoma patients who had previously relapsed whilst on
Vemurafenib or Dabrafenib treatment.
MEK162 (also referred to as ARRY-162 or ARRY-438162)
is a selective ATP-non-competitive inhibitor of MEK1/2 which
inhibits the MEK protein as well as ERK phosphorylation in
numerous cancer cell lines (Roberts and Der, 2007; Yeh et al.,
2007). The phase I study of orally administered MEK162 in 28
patients with biliary tract cancer showed the drug was well tol-
erated and had clinical efficacy in patients. An 8% (n= 2 of 26
patients) overall response rate was observed in this study popula-
tion. One patient was reported to have a complete response with
a PFS of 8.1 months and another subject had a partial response
to treatment with a PFS of 9.8 months. Overall 46% (n= 12) of
patients had stable disease outcomes (Finn et al., 2012). Due to
the overall positive response to treatment reported in this study,
a phase II clinical trial (NCT01320085) investigating the safety
and efficacy of MEK162 in patients with advanced or unresectable
metastatic malignant melanoma, harboring BRAFV600 or NRAS
mutations, is currently underway.
Trametinib (known as GSK1120212 or JTP-74057) is a selec-
tive oral MEK1/2 inhibitor which mediates blockage of the
MAPK kinase MEK protein. Trametinib has been associated
with improved PFS and overall survival in patients harboring
BRAFV600E/K mutations (Falchook et al., 2012a; Flaherty et al.,
2012b). In a phase II trial (NCT01037127), patients harboring
BRAFV600E/K mutant melanoma were given 2 mg of oral Trame-
tinib once daily. Of the patients who were previously treated with
BRAF inhibitors (n= 40), 3% had complete response, 25% stable
disease, and the median PFS was 1.8 months. By contrast, patients
who previously received chemotherapy (n= 57), 4% had com-
plete responses, 30% had partial responses, and 47% stable disease.
This minimal activity observed in patients previously treated with
BRAF inhibitors suggests that BRAF resistant mechanisms may
also confer resistance to MEK inhibitor monotherapy (Kim et al.,
2011).
Following this trial, an ongoing phase III randomized trial
(NCT01245062) was initiated to investigate the efficacy of Tram-
etinib compared to chemotherapy in patients with BRAFV600E/K
advanced or metastatic melanoma. Of the 322 enrolled patients,
214 received Trametinib while 108 received chemotherapy. At the
time of analysis the confirmed overall response rate was 24%
in the Trametinib patients and 7% in the chemotherapy group.
A median PFS of 4.8 months for the Trametinib patients com-
pared to 1.4 months for the chemotherapy patients was reported.
The hazard ratio of overall survival was 0.53 (95% CI 0.30–
0.94; p= 0.0181), favoring the Trametinib subjects. Frequent
adverse events in the Trametinib patients included skin rash, diar-
rhea, edema, hypertension, and fatigue. This study found that,
compared with chemotherapy, Trametinib provided a significant
improvement in progression-free and overall survival for patients
with metastatic melanoma (Robert et al., 2012).
COMBINATION TARGETED THERAPIES
More recently, greater improvements have been noted in
metastatic melanoma patients treated with combination targeted
therapies, particularity so the combination of BRAF (Dabrafenib)
and MEK (Trametinib) inhibitors (Flaherty et al., 2012a). When
used as a single-agent Dabrafenib, like Vemurafenib, has shown
patients developing resistance after approximately 5–7 months
(Falchook et al., 2012b; Hauschild et al., 2012; Long et al.,
2012). Therefore the rationale for adding a MEK inhibitor is
that it may block the escape route for the BRAF inhibitor
and allow continual response and remission in patients. The
phase I clinical trial NCT01072175 tested the combination of
oral Dabrafenib (150 mg) and Trametinib (2 mg) compared
to Dabrafenib (150 mg) alone in 162 patients with metastatic
melanoma containing the BRAFV600E/K mutation. The Dabrafenib
group (n= 54) had a median PFS of 5.8 months compared with
a 9.4 month PFS in the combination group (n= 54) (Flaherty
et al., 2012a). Currently the phase III trial (NCT01682083) is
underway in metastatic BRAFV600 mutated melanoma patients
comparing treatment combinations of Dabrafenib and Trametinib
versus Dabrafenib alone. Other clinical trials currently recruiting
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patients with advanced or metastatic melanoma using the com-
bination of Trametinib and Dabrafenib include NCT01619774,
NCT01584648, NCT 01072175, and NCT01597908.
KIT INHIBITORS
Activating mutations in c-KIT result in stimulation of the MAPK
and PI3K-Akt pathways causing increased proliferation and sur-
vival advantages (Figure 1) (Webster et al., 2006). The c-KIT
inhibitor Sunitinib is a potent inhibitor of mutant KIT with
additional inhibitory effects on VEGF receptors (Chow and Eck-
hardt, 2007). A recent study conducted by Minor et al. showed
that Sunitinib may provide a treatment option for melanoma
patients with KIT mutations. Tumor tissues from 90 patients
with stage III or IV acral, mucosal or cumulative sun-damaged
melanoma were collected. The tumor tissues were sequenced for
KIT, BRAF, NRAS, and GNAQ mutant genes and patients with
amplification or overexpression of KIT were treated with Suni-
tinib. Of the melanoma patients treated with Sunitinib, 11%
had mutations in KIT [other patients presented with mutations
in BRAF (23%), NRAS (14%), or GNAQ (0%)]. Patients pos-
itive for KIT mutations (n= 4; exon 11; W557G, V559G, or
L576P) showed varied responses to the treatment. One patient
had complete remission for 15 months, while two patients demon-
strated partial responses for 1 and 7 months respectively (Minor
et al., 2012). A clinical trial (NCT00859326) is now in progress
investigating the efficacy of a combination of Sunitinib and
Temozolomide (an oral, cytotoxic chemotherapy agent) for the
treatment of metastatic and unresectable malignant melanoma
patients.
Imatinib or Imatinib mesylate (also known as ST1571, Gleevec,
or Glivec) is a receptor protein kinase inhibitor targeting Abl, c-
KIT, and the PDGFR (Fecher et al., 2007; Stuart and Sellers, 2009).
In two phase II trials in patients with metastatic melanoma, Ima-
tinib has shown no response and poor survival outcomes in 16
and 25 patients, respectively (Ugurel et al., 2005; Wyman et al.,
2006). In contrast, a case report revealed that Imatinib may be an
effective treatment, since in one patient with a c-KIT mutation in
exon 11, a positive outcome to the treatment was observed (Hodi
et al., 2008).
More recently the Imatinib inhibitor has been evaluated as a
treatment option in melanoma patients presenting c-KIT muta-
tions (Carvajal et al., 2011; Guo et al., 2011). The phase II trial, in 46
metastatic melanoma patients with c-KIT mutations or amplifica-
tions, demonstrated an overall response rate of 23.3%. All patients
received a continuous dose of 400 mg of Imatinib, unless toxicities
or disease progression occurred. Fifteen patients who experienced
reoccurrence were given an increased dose of 800 mg per day. The
median PFS for the 46 patients was 3.5 months, with a 6-month
PFS rate of 36.6%, and an overall 1-year survival rate of 51%. The
overall rate of disease control was 53.5%. This study found that
Imatinib increased the overall PFS rate, response rate, and overall
survival rate in patients presenting c-KIT mutations in exon 11 and
13. However, patients who had increased doses of Imatinib did not
show improvements in disease control (Guo et al., 2011). Ongoing,
is the phase II clinical trial (NCT00470470), investigating Imatinib
in patients with unresectable stage III or IV melanoma harboring
somatic alterations of c-KIT.
Nilotinib (also known as AMN107) is a second generation tyro-
sine kinase inhibitor known to inhibit KIT, PDGFR, and Bcr-Abl.
It was approved by the FDA in 2010 for the treatment of chronic
myeloid leukemia (CML) and has a similar target profile to Ima-
tinib (Manley et al., 2010). A phase I clinical trial demonstrated
that Nilotinib activity is safe and effective in CML resistant to
treatment with Imatinib (Kantarjian et al., 2006) and a major clin-
ical response was observed to Imatinib in KIT-mutated metastatic
rectal melanoma (Hodi et al., 2008). A current clinical trial
(NCT01168050) is examining Nilotinib as a first or second line
treatment of primary melanoma, stage III unresectable, or stage IV
melanomas with c-KIT mutations or amplifications (NILOMEL).
Another clinical trial (NCT01099514) will also be investigating
Nilotinib in metastatic melanoma with KIT aberrations.
Dasatinib (also known as Bosulif, Sprycel, or BMS-354825) is
a tyrosine kinase inhibitor responsible for inhibiting src family
kinases (c-src, yes, lck, and fyn), Bcr-Abl, c-KIT, PDGFβ recep-
tor, and EPHA2 (Lombardo et al., 2004). Dasatinib was approved
by the FDA for CML and gastrointestinal stromal tumors (GIST)
(von Mehren, 2006; Pavlu and Marin, 2009). A recent single-arm
phase II study of Dasatinib recruited 17 patients with advanced
melanoma. The objective response rate was 5% with evidence
of tumor regression after only four cycles of therapy (n= 5).
The median PFS was 8 weeks. This study revealed that Dasa-
tinib had limited activity in patients with advanced or unre-
sectable melanoma and did not meet the pre-specified response
rate (30%) or the 6-month PFS (Kluger et al., 2011). How-
ever a clinical trial (NCT01092728) is currently recruiting par-
ticipants to investigate Dasatinib monotherapy in patients with
acral lentiginous mucosal or chronic sun-damaged cutaneous
melanoma.
mTOR INHIBITORS
The therapeutic value of targeting the PI3K/AKT pathway in
melanoma has not been as clearly elucidated as it has been for
the MAPK pathway. However, it is clear that an active cross-
talk between these two pathways supports the development of
melanoma and leads to resistance to BRAF inhibitors. Due to the
lack of PI3K and AKT inhibitors currently available for clinical
trial evaluations in melanoma, attention has turned to mTOR for
which several inhibitors are under development.
Temsirolimus, an mTOR inhibitor (also known as CCI-779),
is an analog of Sirolimus (rapamycin) that has demonstrated
immunosuppressive activity against melanoma in preclinical
models and revealed benefits in patients with breast and renal
carcinoma (Hidalgo and Rowinsky, 2000; Huang and Houghton,
2003; Lu et al., 2003). By contrast, an early study demonstrated that
Temsirolimus activity resulted in poor clinical responses and lim-
ited disease PFS rates in metastatic melanoma patients (Margolin
et al., 2005).
While this mTOR inhibitor study diminishes the therapeu-
tic value of targeting the PI3K pathway in melanoma, preclini-
cal evidence has shown, however, that co-targeting this pathway
along with the MAPK pathway remains an important therapeutic
option (Meier et al., 2007). For example, both PI3K and mTOR
inhibitors have revealed synergistic responses when used in combi-
nation therapies with Sorafenib or MEK inhibitors (Molhoek et al.,
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2005; Meier et al., 2007; Lasithiotakis et al., 2008; Chappell et al.,
2011). Interestingly the same response has not been generated
with BRAF inhibitors (Meier et al., 2005; Molhoek et al., 2005).
Current phase I/II clinical trials (NCT00281957, NCT01614301,
and NCT01565837) investigating combination treatments which
include Sorafenib, MEK inhibitors, chemotherapy agents, and
stereotactic ablative radiation therapy along with Temsirolimus
in patients with metastatic melanoma or advanced cancers are
underway.
Another mTOR inhibitor Everolimus (also known as RAD001)
is currently being investigated in patients with metastatic
melanoma in the clinical trial NCT00976573, in which the
chemotherapeutic agents (Carboplatin and Paclitaxel) and Beva-
cizumab are used with Everolimus. Another phase II study
(NCT00521001) investigated the combination of Everolimus
(10 mg daily, for 5 of 7 days) and Temozolomide (200 mg/m2 1–
5 days, every 28 days) in patients (n= 48) with stage IV metastatic
melanoma. From the 48 patients, 8% (n= 4) achieved a partial
response, the median PFS was 2.4 months and the overall survival
was 8.6 months. The combination of Everolimus and Temozolo-
mide did not offer a therapeutic advantage over Temozolomide
alone (Dronca et al., 2010). However, a recent phase I study
investigating the combination of Everolimus with Capecitabine
in patients with advanced solid malignancies demonstrated a pro-
longed clinical benefit for 39% of patients (Deenen et al., 2012).
Currently two clinical trials (NCT01252251 and NCT00976573)
are investigating the therapeutic benefit of Everolimus treatment
plus chemotherapy in patients with melanoma.
From the studies detailed above, it is clear that current
and future clinical trials will focus on implementing several
combination targeted therapies for melanoma patients in the
hope of increasing survival rates and minimizing tumor regres-
sion. Since improved survival rates have been demonstrated in
patients with advanced melanoma, particularly for Vemurafenib
and Dabrafenib, trials are underway to develop novel inhibitors
that target several genes within the MAPK pathways, as these
can be used in combination targeted therapies with the hope
of prolonging PFS. However this strategy is for patients with
BRAF/NRAS/MEK mutations only. For patients with mutations
in alternate pathways (PI3K and AKT) alternate therapies are
required. The lack of efficacy to date, when alternate pathways
are targeted may imply that combination treatments that also
target the MAPK pathways, such as BRAF or MEK inhibitors
together with an mTOR inhibitor, are required to prolong PFS
and to prevent escape mutations. An alternate therapeutic option
is immunotherapy, which is proving to be efficacious (Wilmott
et al., 2012).
IMMUNOTHERAPY THERAPIES
Ipilimumab (also known as Yervoy, MDX-010, or BMS-734016)
a monoclonal antibody to the T-lymphocyte associated antigen
4 (CTLA-4) was approved by the US FDA in March 2011 and it
is currently implemented as a treatment option for patients with
stage III and IV metastatic melanoma. CTLA-4 is member of the
immunoglobulin receptor family essential for the development
of regulatory T-cells. Signaling through this molecule induces
an inhibitory response that abrogates the cytotoxic response of
the T-cells. Blocking this inhibitory signaling allows the tumor
infiltrating lymphocytes to attack the tumors cells.
A phase III clinical trial (NCT00094653) reported by Hodi et al.
(2010) demonstrated an improved survival rate in patients with
unresectable stage III and IV melanoma. These patients received
Ipilimumab either alone (n= 102) or in combination with the
glycoprotein 100 peptide vaccine (gp100) (n= 403) (Hodi et al.,
2010). In another phase III trial (NCT00324155) investigating
Ipilimumab in combination with Dacarbazine for patients with
previously untreated metastatic melanoma overall survival rates
were 47.3% for 1-year, 28.5% for 2-years, and 20.8% for 3-years
(Robert et al., 2011). This study demonstrated a slight improve-
ment in the overall survival responses for patients who received
Ipilimumab-plus Dacarbazine compared with patients who had
received Ipilimumab-plus the gp100 vaccine. Di Giacomo et al.
(2012) have reported on a more recent phase II clinical trial
(NCT01654692) which assessed the combination of Ipilimumab
and Fotemustine in patients with advanced, unresectable stage III
or IV melanoma. A total of 46.5% (n= 40) of the study popula-
tion maintained a stable disease within 12 months and a median
PFS of 5 months (Di Giacomo et al., 2012). More than 50%
(n= 10) of patients with brain metastases survived longer than
12 months, compared to approximately 20% survival reported
for patients undergoing radiotherapy or surgery (Eigentler et al.,
2011). Currently a phase I/II clinical trial (NCT01400451) com-
bining BRAF targeted therapy (Vemurafenib) with immunother-
apy (Ipilimumab) is underway in subjects with BRAFV600E/K
metastatic melanoma as a strategy to prolong PFS.
Other immunotherapeutic agents currently being tested are
antibodies that interfere with the PD-1 (programed death-1)
and PD-L1 (PD-1 ligand). PD-1 is a key immune co-inhibitory
receptor expressed by activated T-cells which mediate immuno-
suppression. The primary function of PD-1 is in peripheral tissue
where T-cells encounter immunosuppressive ligands PD-L1 (also
known as B7-H1 or CD274) and PD-L2 (also referred to as B7-
DC or CD273) which are expressed by tumor and/or stromal cells
(Dong et al., 1999; Menzies et al., 2012; Topalian et al., 2012).
Anti-PD-1 antibodies interfere with the interactions between PD-
1 and PD-L1 allowing the T-cells to attack the tumor cells (Iwai
et al., 2002; Dong et al., 2003). The anti-PD-1 inhibitor mono-
clonal antibody MDX-1106 (also referred to as BMS-936558 and
ONO-4538) showed favorable preliminary evidence when admin-
istrated as a single-agent in a pilot study involving 39 patients with
advanced solid tumors (Brahmer et al., 2010). In another study
amongst participants with melanoma (n= 94), 28% (n= 26) had
objective responses, lasting for 1 year or more (Topalian et al.,
2012). Various trials are underway comparing the clinical benefit
and overall survival after treatment with this anti-PD-1 antibody
(NCT01621490, NCT01176474, and NCT01721772). MK-3475 is
another anti-PD-1 inhibitor which is being investigated in a phase
I clinical trial (NCT01295827). Encouraging anti-tumor activity
was reported at the recent Society for Melanoma Research Con-
gress in November 2012 (Hamid, 2012). Objective anti-tumor
responses were recorded in 51% (n= 43) of 85 patients analyzed
to date. Of those 9% (n= 8) of patients demonstrated a com-
plete response to MK-3475. Furthermore, a study conducted by
Brahmer et al. (2012) has shown that the anti-PD-L1 antibody
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BMS-936559 provides durable tumor responses in patients with
advanced cancer including melanoma. These results validate the
interaction between PD-1 and PD-L1 as an important target for
therapeutic intervention in melanoma patients.
In general the anti-PD-1 and anti-PD-L1 treatments have
achieved the highest rate of anti-tumor activity reported for
an immunotherapeutic agent in the past 30 years (Ribas, 2012).
Together with Ipilimumab, these immunotherapeutic agents have
demonstrated an increased durability of the tumor response (Hodi
et al., 2010; Brahmer et al., 2012; Topalian et al., 2012). Their
low response rate compared to targeted therapies such as the
BRAFV600E inhibitors support their use in combination therapies.
With two different modes of action, combination therapies that
together target both cellular proliferation and immune response
might provide enhanced inhibition of the spread of melanoma,
and may overcome the development of drug resistance.
RESISTANCE TO BRAF INHIBITORS AND COMBINATION
THERAPIES
Although there have been encouraging results with targeted BRAF
inhibitors, such as Vemurafenib and Dabrafenib (Hauschild et al.,
2012; Sosman et al., 2012), almost all patients on these thera-
pies develop drug resistance after the initial response, leading to
clinical relapse. The underlying reasons for the development of
drug resistance can be found in the redundancy of molecular
and cellular processes that mediate the development of melanoma
(Figure 1). Significant efforts have been dedicated to the study
of acquired resistance to BRAF inhibitors. Results from various
groups indicate that resistance to BRAF inhibition can be attrib-
uted to a series of heterogeneous mechanisms that lead to the
reactivation of the MAPK pathway. These mechanisms of reactiva-
tion include upregulation of NRAS through activating mutations
(Q61K/R) (Nazarian et al., 2010), overexpression of COT/Tp12 by
increased copy number of the MAP3K8 locus (Johannessen et al.,
2010), activation of MEK1 by mutation C121S (Wagle et al., 2011),
alternative BRAF splicing (Poulikakos et al., 2011), or BRAFV600E
gene amplification (Shi et al., 2012b). Alternative, resistance is
achieved by the activation of PI3K-AKT and RAS-CRAF-MEK
pathways through receptor tyrosine kinase (RTK) signaling. Such
activation includes, overexpression of platelet-derived growth fac-
tor β (PDGFβ) (Nazarian et al., 2010; Shi et al., 2012b) and
activation of IGF1R (Villanueva et al., 2010). Interestingly, all
these escape mechanisms are largely mutually exclusive and dif-
fer between patients and in some cases between tumors within a
patient (Nazarian et al., 2010; Shi et al., 2012b).
MEK MUTATION
Wagle et al. (2011) profiled tumors sensitive and resistant to
BRAF inhibitors by massive parallel sequencing and identified the
reactivation of the MAPK pathway by a newly identified muta-
tion, MEK1C121S. MEK1C121S also confers cross-resistance to the
MEK inhibitor Selumetinib. However, this mutation has not been
observed in any other studies of Vemurafenib-resistant tumors
since then (Shi et al., 2012b). On the other hand, commonly found
MEK exon 3 activating mutations such as MEKP124S and MEKI111S
are shown to not confer Vemurafenib resistance (Shi et al., 2012a).
Escape through a MEK activating mutation is therefore unusual
and in contrast to most other mechanisms of acquired drug resis-
tance, where the activation emerges downstream of the targeted
kinase (Wagle et al., 2011).
NRAS MUTATIONS
Nazarian et al. demonstrated that acquired resistance to Vemu-
rafenib developed in melanoma cell lines and patient tumors by
the acquisition of NRAS mutations. Interestingly, two biopsies
from the same patient had two different activating NRAS muta-
tions (NRASQ61R and NRASQ61K) (Nazarian et al., 2010). More
recently Shi et al. (2012b) reported that 5 of 15 patients with disease
progression after responding to Vemurafenib, carried NRAS muta-
tions. The NRAS mutated cells were sensitive to the MEK inhibitor,
Selumetinib, in the presence or absence of Vemurafenib, suggest-
ing that reactivation of the MAPK pathway might have occurred
via CRAF bypassing the BRAF inhibition. This was later con-
firmed by re-sensitization of a cell line (NRASQ61K/BRAFV600E)
to Vemurafenib by knocking down CRAF expression (Shi et al.,
2012b).
COT OVEREXPRESSION
Through the screening of an “open reading frame” expression
library encoding approximately 75% of the human kinases, Johan-
nessen et al. (2010) identified that overexpression of COT/Tpl2
and CRAF reduced sensitivity to BRAF inhibitor PLX4720 (a
preclinical version of Vemurafenib). Moreover, increased COT
transcript levels were observed in two biopsies collected during
Vemurafenib treatment and compared to lesion-matched pre-
treatment biopsies. Furthermore, high levels of COT expression
were related to an increased copy number of the MAP3K8 locus
in two cell lines resistant to PLX4720. Over-activation of MEK
in the melanoma cell line A375 through COT signaling resulted
in resistance to the MEK inhibitors Selumetinib and CI-1040.
Nevertheless, the authors found that co-inhibition of both BRAF
and MEK can overcome resistance to BRAF inhibitors caused by
increased COT levels.
REACTIVATION OF BRAF
Contrary to intuition, no compensatory BRAF mutations have
been found as a mechanism of resistance to BRAF inhibitors.
However, reactivation of tumor progression after response to
BRAF inhibitors can be achieved by tumor cells with an increased
copy number of BRAFV600E. Indeed, Shi et al. (2012b) demon-
strated that 20% of melanoma patients treated with BRAF
inhibitors (Vemurafenib and Dabrafenib) showed an increase in
genomic copy number of BRAFV600E and BRAFV600E amplifica-
tion resulted in BRAFV600E overexpression in tumors of melanoma
patients whose cancer had progressed after initial response. Cell
lines with BRAFV600E gene amplification, thus resistant to BRAF
inhibitors, remained sensitive to Selumetinib, with Vemurafenib
and Selumetinib combination therapy producing a synergistic
effect.
Poulikakos et al. identified BRAFV600E splicing variants which
lack a RAS-binding domain (RBD) in two cell lines. These cell lines
displayed acquired resistance to Vemurafenib, that could not be
explained by mechanisms previously described (Poulikakos et al.,
2011). The observed truncated form of BRAF (p61BRAF) was
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the result of an in-frame deletion of exons 4–8. While the mech-
anism underlying this exon skipping phenomena remains to be
identified, exons 4–8 encode domains essential for RAF activation,
including the RBD and the cysteine-rich domain (CRD) (Well-
brock et al., 2004). The truncated BRAF lacking the RBD is able
to dimerize independently of RAS signaling. Introduction of a
mutation that abolishes p61BRAF dimerization restored sensitiv-
ity to Vemurafenib. Confirming this as a mechanism of resistance,
BRAF variants lacking the RBDs were found in 6 of the 19 patients
undergoing Vemurafenib treatment (Poulikakos et al., 2011), while
Shi et al. (2012b) reported the same mechanism in another two
patients. P61BRAFV600E expressing cells remained sensitive to the
MEK inhibitor Selumetinib. It is possible that these mechanisms of
resistance may benefit from dose-escalation of the BRAF inhibitor,
such as Dabrafenib, for which, the maximum tolerated dose has
not yet been determined.
RTK ACTIVATION
In addition to the above mechanisms of acquired resistance to
BRAF inhibitors, RTK overexpression or activation has been
shown to bypass mutant BRAF and reactivate ERK through
CRAF-MEK or via ERK independent mechanisms by activating
the PI3K/AKT pathways. Upregulation of PDGFRβ and EGFR
were demonstrated to mediate resistance to Vemurafenib devel-
oped in melanoma cell lines by Nazarian et al. (2010). In par-
ticular PDGFRβ displayed increased activation associated with
tyrosine phosphorylation. Moreover the authors found that 4 of
11 post-relapse biopsies from melanoma patients treated with
Vemurafenib showed increased expression of PDGFRβ in com-
parison to pre-treatment biopsies. The same increase was also
observed in three relapse tumor biopsies from a patient treated
with Dabrafenib (Shi et al., 2012b).
Platelet-derived growth factor receptor β knockdown by RNAi
in resistant cell lines led to re-sensitization of the growth inhibi-
tion by Vemurafenib, but did not activate the apoptotic response
(Nazarian et al., 2010). Thus, PDGFRβ overexpression might not
be the only mechanism of resistance in these cells. Moreover, the
PDGFRβ inhibitor Imatinib or the MEK inhibitor Selumetinib
did not restore sensitivity to Vemurafenib (Shi et al., 2011). It is
possible that resistance may involve the activation of more than
one RTK.
BRAF inhibitor resistance also has been demonstrated to occur
via phospho-activation of the RTK, IGF1R, with subsequent
downstream activation of the PI3K/AKT pathways (Villanueva
et al., 2010). Inhibition of IGF1R led to slower cell survival, but
little improvement was observed when added in combination with
the BRAF inhibitor. IGFR inhibition diminished pAKT activation,
but did not suppress pMEK/pERK activation. Combination IGF1R
inhibitor, PPP, with a MEK inhibitor, Trametinib, led to increased
apoptosis and decreased cell viability (Villanueva et al., 2010).
Two recent reports showed RTK-mediated resistance to BRAF
inhibition in colorectal carcinoma (Corcoran et al., 2012; Pra-
hallad et al., 2012). Both studies showed activation of EGFR and
downstream pathways (PI3K/AKT and MEK/ERK). All these stud-
ies underscore the role of RTK expression and activation in BRAF
inhibitor acquired resistance. Given the redundancy and promis-
cuity of the RTKs signaling in melanoma cells, RTK reprograming
might not effectively halt tumor growth. This leads to a propo-
sition that co-targeting MEK, and the PIK/AKT/mTOR pathway
would be a more effective strategy in response to this type of BRAF
inhibitor induced resistance (Lo, 2012).
MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR
CELLS FOR PERSONALIZED TREATMENT MONITORING
Targeted cancer therapies are effective in only a proportion of
patients. For effective therapy accurate molecular analysis of a
patient’s tumors is required, as incorrect administration can neg-
atively impact on patient survival. Molecular tools are required
that determine which patients are likely to benefit from the ther-
apy and reveal, early during treatment, whether the therapy is
effective. The quantification and molecular profiling of circulating
tumor cells (CTCs) has been proposed as an aiding method-
ology for tumor genotyping and for early detection of therapy
efficacy.
Several studies have investigated the value of detecting CTCs in
melanoma patients by multimarker RT-PCR to predict response
to therapeutic regimens with mixed outcomes. Reynolds et al.
(2003) observed that therapy with a polyvalent melanoma vac-
cine was associated with clearance of melanoma cell markers
(tyrosinase, gp100, MART-1, and MAGE-3) from the circulation
and improved prognosis. Monitoring of CTCs by expression of
five melanoma-associated biomarkers (MART-1, GalNAc-T, PAX-
3, MAGE-A3, and MITF) in patients receiving biochemotherapy
and maintenance biotherapy for stage IV melanoma suggests that
CTCs detection may be useful for predicting therapeutic effi-
cacy and disease outcome (Koyanagi et al., 2010; Reid et al.,
2013). In a multivariate analysis, pre-treatment and serial CTC
positivity (MART-1, MAGE-A3, and PAX-3 RT-PCR) was sig-
nificantly associated with disease-free survival and overall sur-
vival (Hoshimoto et al., 2012) (NCT00052156). However, Fusi
et al. (2012) reported that although CTCs positivity (Mart-1
and tyrosinase) was time dependant prognostic factor, it was
not predictive of treatment outcome. Overall, CTC quantification
using RT-PCR has been deemed prone to false positive results
and the lack of validated and standardized methodologies has
preclude its use as a biomarker in clinical trials (Nezos et al.,
2009).
Several methodologies have been developed for cytometric
detection of CTCs. At the fore front of these is the CellSearch
system. Using this platform CTCs have been detected in cancer
patients at both early and late stages, with the number of tumor
cells in peripheral blood showing significant utility for progno-
sis in breast, colorectal, prostate, and non-small-cell lung cancers
(Cristofanilli et al., 2004; Cohen et al., 2008; de Bono et al., 2008;
Krebs et al., 2011). More recently, Khoja et al. demonstrated that
CTCs were detectable in 40% of patients with advance cutaneous
melanoma and the number of CTCs was prognostic for overall
survival. They also showed preliminary evidence that changes in
the number of CTCs during treatment may reflect outcome (Khoja
et al., 2012). Currently additional trials are underway investigating
the prognostic and predictive value of CTCs to identify respond-
ing patients treated with Ipilimumab (NCT01565837), Imatinib
(NCT00470470), Everolimus (NCT00976573), and BRAFV600E
inhibitors (NCT01573494).
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Circulating tumor cells not only constitute seeds for metastases
and indicate the spread of the disease, but they also reflect the
tumors within a patient, thus genetic changes in tumors could be
readily detected in CTCs. Thus, CTCs could constitute an accessi-
ble sample with which to analyze the genetic profile of the tumors
in a particular individual and possibly better represent the muta-
tion status of all the tumors within a patient than a single biopsy.
The detection of the BRAFV600E mutation in CTCs isolated from
melanoma patients has been previously reported (Kitago et al.,
2009; Freeman et al., 2012). A recent report by Sakaizawa et al.
(2012) successfully identified BRAF and KIT activating muta-
tions at a single cell level in CTCs from patients with melanoma.
Another study also showed the detection of BRAFV600E in CTCs
with a 91% (19/21) correspondence with the matched tumor tis-
sue. Moreover, in one of those individuals CTCs were shown to
bear the BRAFV600E mutation while this was not present at the
tissue level, again suggesting that the CTCs reflect the hetero-
geneity of the tumors (Fusi et al., 2011). This is consistent with
previous observations of intra- and inter-tumor heterogeneity
of BRAF mutation status in melanoma (Sensi et al., 2006; Yan-
covitz et al., 2012). Inter- and intra-tumor heterogeneity have
been identified in several tumor types and it has been shown
to affect responses to targeted therapies in GIST and lung can-
cer (Liegl et al., 2008; Taniguchi et al., 2008). Given the diverse
clinical responses of melanoma patients to BRAF inhibitors, stud-
ies on the association between tumor heterogeneity and clinical
outcome are needed. In this context, CTCs could constitute an
accessible sample with which to analyze the genetic profile of the
tumors in a particular individual and possibly better represent the
mutation status of all the tumors within a patient than a single
biopsy.
Molecular characterization of CTCs for personalized treat-
ment monitoring has been demonstrated in other tumors besides
melanoma. For example Maheswaran et al. (2008) described a suc-
cessful molecular analysis of CTCs from patients with metastatic
non-small-cell lung cancer. The drug resistance mutation T790M
was detected in CTCs collected from patients with EGFR muta-
tions that had received tyrosine kinase inhibitors Gefitinib (Iressa)
or Erlotinib (Tarceva). The presence of the mutation corre-
lated with reduced PFS from 16.5 to 7.7 months (p< 0.001).
This result supports the idea of monitoring changes in tumor
genotypes during the course of treatment, by genotyping CTCs.
Similarly, the presence of KRAS mutations in EGFR-positive col-
orectal cancer partially explains why these tumors do not respond
to anti-EGFR mAb Cetuximab (Erbitux). Molecular analysis of
the primary tumor determines the suitability of this targeted
therapy, however discordances in the KRAS mutational status
between the primary and metastatic tumors have been reported
in a small subset of patients with metastatic colorectal cancer
(Artale et al., 2008; Italiano et al., 2010). This could explain
the observed resistance in some patients despite having a wild-
type KRAS primary tumor. Yang et al. (2010) detected the KRAS
mutation in blood CTCs and suggested that the blood might
be a better sample to assess the tumor genotype for treatment
decisions.
Chromosomal amplification of androgen receptor (AR),
rearrangement of ERG gene, PTEN deletion, and MYC amplifica-
tion were detected in CTCs from patients with metastatic prostate
cancer by FISH (Attard et al.,2009; Leversha et al.,2009). Moreover,
Attard and colleagues demonstrated that CTCs, metastases and
prostate tissue invariably had the same ERG gene status in therapy-
naive prostate cancer patients. However, significant heterogeneity
of AR copy number gain and PTEN loss were observed in CTCs,
illustrating the heterogeneity of the tumors and the representation
of this diversity in CTCs.
Altogether these observations support CTCs as a superior
sample with which to examine the genetic profile of the sum
of the patient’s tumors and may therefore be useful for moni-
toring the development of escape mutations during treatment.
Nevertheless, prior studies that isolate and analyze CTCs are
limited in that they concentrate on methodologies that utilize
only one or two surface proteins, gene deletions, amplifications,
or point mutations. More comprehensive studies are required
that determine the extent to which CTCs represent the parental
tumors. The rapid progress in next generation sequencing and
onco-proteomics will enable in the near future, better character-
ization of CTCs. Hopefully this will uncover more informative
biomarkers with which to select CTCs and thus provide more
specific information about patients who will benefit from tar-
geted treatments as well as improve evaluation of therapeutic
responses.
In parallel, improvements in the methodologies used to iso-
late and quantify CTCs are needed. Different methodologies that
bias toward different tumor cell subsets might not reflect the
overall tumor(s) heterogeneity. Issues such as collective migra-
tion (microemboli), epithelial-mesenchymal transition (EMT),
and metastatic potential of the CTCs still need to be addressed
in the context of well designed clinical trials with highly sensi-
tive molecular analyses to determine which procedures provide
the best prediction of clinical treatment outcomes. It is likely that
this will be different for different cancer types and therapeutic
interventions. The use of CTCs as a companion to treatments is a
valuable tool that should be evaluated as part of therapy clinical
trials to facilitate a swift implementation into clinical practice.
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